The Future of Medicine, Made Accessible
Biopharmaceuticals are transforming the future of medicine and Major Healthcare is helping bring that future to emerging markets. We provide access to advanced biologics and biosimilars, supporting partners with the products, formats, and expertise needed to expand care and reduce treatment costs in high-burden disease areas.
We offer flexible supply formats, including bulk biologics, finished dosages, and private label-ready solutions—all supported by GMP-certified partners and global regulatory experience.
Our Key Focus Areas
Oncology Biosimilars: A growing range of cost-effective monoclonal antibodies and biologics for cancer care, available in vials, ampoules, and powder form—serving both hospital protocols and outpatient treatment programs.
Immunology Biologics: From autoimmune therapies to targeted biosimilars, we offer finished and bulk biologics to support immune system regulation, local production, and customizable packaging solutions.
Cardiovascular Biologics: Peptide-based therapies and biologics for atherosclerosis, hyperlipidemia, and clotting disorders—available in injectable formats and bulk packaging for institutional and hospital use.
Diabetes Biologics: Biosimilar insulins and GLP-1 therapies that improve glycemic control and access, offered in vials, pre-filled pens, and bulk formats for public tenders, private label, or institutional use.
A Strong Focus on Biosimilars
We believe biosimilars are the key to sustainable access. That’s why we prioritize biologics that deliver the same clinical outcomes at lower cost—expanding access to life-changing treatments for oncology, diabetes, and immunology. Our team can support you with:
- Sourcing biosimilars from trusted partners
- Local registration support and dossier access
- Flexible commercial formats: from vials to prefilled pens
- Private label and packaging-ready options for tenders and market launches.